New York State Common Retirement Fund Sells 32,134 Shares of Organon & Co. (NYSE:OGN)

New York State Common Retirement Fund decreased its position in shares of Organon & Co. (NYSE:OGN) by 14.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 190,749 shares of the company’s stock after selling 32,134 shares during the quarter. New York State Common Retirement Fund owned approximately 0.07% of Organon & Co. worth $2,751,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Harvest Fund Management Co. Ltd lifted its stake in shares of Organon & Co. by 495.5% during the third quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the period. Lindbrook Capital LLC raised its holdings in Organon & Co. by 348.3% during the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after purchasing an additional 1,428 shares during the last quarter. Headlands Technologies LLC acquired a new position in Organon & Co. during the 3rd quarter valued at about $35,000. EverSource Wealth Advisors LLC lifted its position in Organon & Co. by 97.7% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company’s stock valued at $39,000 after purchasing an additional 1,110 shares during the period. Finally, Clear Street Markets LLC boosted its stake in shares of Organon & Co. by 588.9% in the 3rd quarter. Clear Street Markets LLC now owns 2,294 shares of the company’s stock valued at $40,000 after purchasing an additional 1,961 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

OGN has been the subject of a number of recent research reports. The Goldman Sachs Group boosted their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday. Piper Sandler upped their target price on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, April 29th.

Organon & Co. Trading Up 5.5 %

Organon & Co. stock opened at $20.68 on Tuesday. The firm has a market capitalization of $5.32 billion, a P/E ratio of 5.02, a PEG ratio of 0.88 and a beta of 0.81. The business has a 50-day moving average of $18.19 and a 200-day moving average of $15.76. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.08.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a net margin of 16.50% and a negative return on equity of 259.73%. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Research analysts anticipate that Organon & Co. will post 4.1 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Monday, May 13th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 5.42%. The ex-dividend date is Friday, May 10th. Organon & Co.’s dividend payout ratio (DPR) is 27.38%.

Insider Activity at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver bought 2,720 shares of Organon & Co. stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the acquisition, the insider now owns 15,181 shares in the company, valued at approximately $278,723.16. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.17% of the stock is owned by corporate insiders.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.